Inscription Capital LLC Takes $1.01 Million Position in Insulet Corporation $PODD

Inscription Capital LLC purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,259 shares of the medical instruments supplier’s stock, valued at approximately $1,006,000.

A number of other large investors have also added to or reduced their stakes in PODD. True Wealth Design LLC grew its holdings in Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 72 shares during the last quarter. Golden State Wealth Management LLC grew its stake in shares of Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 69 shares during the last quarter. Trust Co. of Toledo NA OH acquired a new stake in Insulet in the second quarter valued at $35,000. Quent Capital LLC acquired a new stake in Insulet in the third quarter valued at $49,000. Finally, Osterweis Capital Management Inc. bought a new position in Insulet during the 2nd quarter worth $51,000.

Wall Street Analysts Forecast Growth

PODD has been the subject of several recent research reports. Wolfe Research increased their price target on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Jefferies Financial Group boosted their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Wells Fargo & Company increased their price objective on shares of Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. BTIG Research lifted their target price on shares of Insulet from $370.00 to $380.00 and gave the stock a “buy” rating in a research note on Friday, November 21st. Finally, Zacks Research cut shares of Insulet from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Twenty-one analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $379.10.

Insulet Stock Down 1.2%

Shares of NASDAQ PODD opened at $284.25 on Wednesday. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The firm has a market cap of $20.00 billion, a PE ratio of 82.39, a P/E/G ratio of 1.60 and a beta of 1.40. The company’s fifty day simple moving average is $301.80 and its 200 day simple moving average is $310.75. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The business’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.08 earnings per share. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.